Control Empresarial de Capitales S.A. de C.V. - 28 Apr 2026 Form 4 Insider Report for PROKIDNEY CORP. (PROK)

Reporting relationship: Other*, 10%+ Owner
Issuer ticker: PROK
Reported as of: 28 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Apr 2026, 16:12:46 UTC
Prior SEC filing: 08 Apr 2026
Next SEC filing: 30 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Victor Manuel Gutierrez Lopez, Attorney-in-Fact

Filing notes and source

Key filing fact

Control Empresarial de Capitales S.A. de C.V. filed Form 4 for PROKIDNEY CORP. (PROK) on 30 Apr 2026.

Key facts

This page summarizes Control Empresarial de Capitales S.A. de C.V.'s Form 4 filing for PROKIDNEY CORP. (PROK).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Apr 2026, 16:12.

Change

Previous filing in this sequence was filed on 08 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001273693 Primary reporting owner

Control Empresarial de Capitales S.A. de C.V.

Relationship: Other*, 10%+ Owner
Address: PASEO DE LAS PALMAS 781, PISO 6, LOMAS DE CHAPULTEPEC, CIUDAD DE MEXICO, MEXICO
Signature: /s/ Victor Manuel Gutierrez Lopez, Attorney-in-Fact
Signature date: 30 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PROK transaction

Class A Common Shares (as defined in Exhibit 99.1 hereto)

Conversion of derivative security

Transaction value
Shares: +63,118,645
Change %: +589%
Price: $0.000000^*
Shares after: 73,842,723
Date: 28 Apr 2026
Ownership: Direct
Footnotes: F1, F2, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PROK transaction Derivative

Class B Common Shares

Conversion of derivative security

Transaction value
Shares: -63,118,645
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Apr 2026
Ownership: Direct
Underlying class: Class A Common Shares
Underlying amount: 63,118,645
Exercise price
Footnotes: F1, F3, F4, F6

PROK transaction Derivative

Common Units in ProKidney LLC

Conversion of derivative security

Transaction value
Shares: -63,118,645
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Apr 2026
Ownership: Direct
Underlying class: Class A Common Shares
Underlying amount: 63,118,645
Exercise price
Footnotes: F1, F3, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Prior to April 28, 2026 (the "Transaction Date"), the reporting persons beneficially owned 63,118,645 Class B Common Shares, $0.0001 par value per share (the "Class B Common Shares") of ProKidney Corp. (the "Issuer"), each of which may, subject to the limitations set forth in the Amended and Restated Exchange Agreement (the "Exchange Agreement") and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, be exchanged, together with the paired common unit (a "Common Unit," and together with the Class B Common Shares, the "Paired Interests") in ProKidney Holdings, LLC ( "ProKidney LLC"), for a Class A Common Share on a one-for-one basis. Prior to the Transaction Date, the reporting person owned 63,118,645 Paired Interests. On the Transaction Date, the reporting person exchanged 63,118,645 Paired Interests for 63,118,645 Class A Common Shares.

Footnote F2

The Form 4 filed by the reporting person on March 16, 2024 and prior to the date hereof inadvertently aggregated 63,118,645 Paired Interests in Table I.

Footnote F3

At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement, each Class B Common Share, together with a paired Common Unit, may be exchanged for a Class A Common Share on a one-for-one basis.

Footnote F4

The Class B Common Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Common Shares do not expire.

Footnote F5

The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.

Footnote F6

See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference.